Dec 19, 2022
GlyTherix Ltd (“GlyTherix”), an Australian immune-oncology company today announced an MTA & Option License with Adcendo ApS (“Adcendo”), a Danish biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
May 3, 2022
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Copenhagen, Denmark, May...
Apr 12, 2022
The poster presentation highlights the preclinical evaluation of several of Adcendo´s ADC candidates for the treatment of osteosarcoma Copenhagen, Denmark, April 11th, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of...
Dec 1, 2021
Building the team with experienced biotech experts and renowned leaders in the ADC fieldUnderscores company’s commitment to progressing lead program on novel ADC target uPARAP Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the...
Jul 6, 2021
Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael...
Apr 29, 2021
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech companyPlans to build a pipeline of ADCs directed at novel...
